Drug allergy passport and other documentation for patients with drug hypersensitivity: An ENDA/EAACI Drug Allergy Interest Group Position Paper
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Drug allergy passport and other documentation for patients with drug hypersensitivity : An ENDA/EAACI Drug Allergy Interest Group Position Paper. / Brockow, Knut; Aberer, Werner; Atanaskovic-Markovic, M; Bavbek, Sevim; Bircher, Andreas; Bilo, Beatrice M; Blanca, Miguel; Bonadonna, Patrizia; Burbach, G; Calogiuri, G; Caruso, C.; Celik, G; Cernadas, J; Chiriac, A M; Demoly, P; Oude Elberink, J N G; Fernandez, J; Gomès, E.; Garvey, L H; Gooi, J; Gotua, M; Grosber, M; Kauppi, P; Kvedariene, V; Gómez-Laguna, J.; Makowska, J S; Mosbech, H; Nakonechna, A; Papadopolous, N G; Ring, J; Romano, A; Rockmann, H; Sargur, R; Sedlackova, L; Sigurdardottir, S; Schnyder, Benno; Storaas, T; Torres, Mina; Zidarn, M; Terreehorst, Ingrid.
I: Allergy: European Journal of Allergy and Clinical Immunology, Bind 71, Nr. 11, 11.2016, s. 1533-1539.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Drug allergy passport and other documentation for patients with drug hypersensitivity
T2 - An ENDA/EAACI Drug Allergy Interest Group Position Paper
AU - Brockow, Knut
AU - Aberer, Werner
AU - Atanaskovic-Markovic, M
AU - Bavbek, Sevim
AU - Bircher, Andreas
AU - Bilo, Beatrice M
AU - Blanca, Miguel
AU - Bonadonna, Patrizia
AU - Burbach, G
AU - Calogiuri, G
AU - Caruso, C.
AU - Celik, G
AU - Cernadas, J
AU - Chiriac, A M
AU - Demoly, P
AU - Oude Elberink, J N G
AU - Fernandez, J
AU - Gomès, E.
AU - Garvey, L H
AU - Gooi, J
AU - Gotua, M
AU - Grosber, M
AU - Kauppi, P
AU - Kvedariene, V
AU - Gómez-Laguna, J.
AU - Makowska, J S
AU - Mosbech, H
AU - Nakonechna, A
AU - Papadopolous, N G
AU - Ring, J
AU - Romano, A
AU - Rockmann, H
AU - Sargur, R
AU - Sedlackova, L
AU - Sigurdardottir, S
AU - Schnyder, Benno
AU - Storaas, T
AU - Torres, Mina
AU - Zidarn, M
AU - Terreehorst, Ingrid
N1 - © 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
PY - 2016/11
Y1 - 2016/11
N2 - The strongest and best-documented risk factor for drug hypersensitivity (DH) is the history of a previous reaction. Accidental exposures to drugs may lead to severe or even fatal reactions in sensitized patients. Preventable prescription errors are common. They are often due to inadequate medical history or poor risk assessment of recurrence of drug reaction. Proper documentation is essential information for the doctor to make sound therapeutic decision. The European Network on Drug Allergy and Drug Allergy Interest Group of the European Academy of Allergy and Clinical Immunology have formed a task force and developed a drug allergy passport as well as general guidelines of drug allergy documentation. A drug allergy passport, a drug allergy alert card, a certificate, and a discharge letter after medical evaluation are adequate means to document DH in a patient. They are to be handed to the patient who is advised to carry the documentation at all times especially when away from home. A drug allergy passport should at least contain information on the culprit drug(s) including international nonproprietary name, clinical manifestations including severity, diagnostic measures, potential cross-reactivity, alternative drugs to prescribe, and where more detailed information can be obtained from the issuer. It should be given to patients only after full allergy workup. In the future, electronic prescription systems with alert functions will become more common and should include the same information as in paper-based documentation.
AB - The strongest and best-documented risk factor for drug hypersensitivity (DH) is the history of a previous reaction. Accidental exposures to drugs may lead to severe or even fatal reactions in sensitized patients. Preventable prescription errors are common. They are often due to inadequate medical history or poor risk assessment of recurrence of drug reaction. Proper documentation is essential information for the doctor to make sound therapeutic decision. The European Network on Drug Allergy and Drug Allergy Interest Group of the European Academy of Allergy and Clinical Immunology have formed a task force and developed a drug allergy passport as well as general guidelines of drug allergy documentation. A drug allergy passport, a drug allergy alert card, a certificate, and a discharge letter after medical evaluation are adequate means to document DH in a patient. They are to be handed to the patient who is advised to carry the documentation at all times especially when away from home. A drug allergy passport should at least contain information on the culprit drug(s) including international nonproprietary name, clinical manifestations including severity, diagnostic measures, potential cross-reactivity, alternative drugs to prescribe, and where more detailed information can be obtained from the issuer. It should be given to patients only after full allergy workup. In the future, electronic prescription systems with alert functions will become more common and should include the same information as in paper-based documentation.
KW - Journal Article
U2 - 10.1111/all.12929
DO - 10.1111/all.12929
M3 - Journal article
C2 - 27145347
VL - 71
SP - 1533
EP - 1539
JO - Allergy: European Journal of Allergy and Clinical Immunology
JF - Allergy: European Journal of Allergy and Clinical Immunology
SN - 0105-4538
IS - 11
ER -
ID: 178966855